Author:
Alnaqbi Khalid A,Elezbawy Baher,Fasseeh Ahmad N,Bangash Abdul Rauf,Elshamy Amin,Shendi Hiba,Aftab Mohammed I,AlMarshoodi Mozah,Gebran Nicole,AlDhaheri Noura,Fahmy Sahar A,Al Dallal Sara,Al Naeem Waeil,Abaza Sherif,Kaló Zoltán
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. EC/847/2000 Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal prod. (2022). Accessed. July 11, 2022: https://www.gmp-compliance.org/guidelines/gmp-guideline/ec-847-2000-commission-regulation-ec-no-847-2000-of-27-april-....
2. Orphan drugs: major development challenges at the clinical stage;Fonseca DA;Drug Discov Today,2019
3. Rare diseases, orphan drugs, and orphan diseases;Aronson J;BMJ,2006
4. Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR Rare Disease Special Interest Group;Nestler-Parr S;Value Health,2018
5. Rare Diseases. Regulatory incentives for development of orphan drugs - the United States & Europe. (2021). Accessed: July 31, 2022: https://credevo.com/articles/2019/12/15/rare-diseases-regulatory-incentives-for-development-of-orphan-drugs-us-europe/.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献